Table 5.
Comparisons of clinical characteristics according to disease progression in patients with subnephrotic range proteinuria
| Progression to NS (N = 26) | No progressiona (N = 39) | P-value | |
|---|---|---|---|
| Male | 9 (34.6%) | 23 (58.9%) | 0.124 |
| Age (years) | 53 ± 11 | 47 ± 13 | 0.088 |
| BMI (kg/m2) | 23.5 ± 2.3 | 23.9 ± 2.8 | 0.513 |
| Hypertension | 8 (28.6%) | 8 (20.5%) | 0.558 |
| Serum creatinine (mg/dl) | 0.90 ± 0.18 | 1.11 ± 0.80 | 0.230 |
| Serum albumin (g/dl) | 2.67 ± 0.61 | 3.36 ± 0.48 | <0.001 |
| Serum cholesterol (mg/dl) | 274.1 ± 92.4 | 225.3 ± 62.4 | 0.018 |
| CKD stage according to eGFR | 0.399 | ||
| Stage I | 14 (53.8%) | 14 (35.9%) | |
| Stage II | 10 (38.5%) | 18 (46.1%) | |
| Stage III | 1 | 4 (10.3%) | |
| Stage IV-V | 1 | 3 (7.7%) | |
| Serum hemoglobin (g/dL) | 12.4 ± 2.2 | 13.4 ± 1.9 | 0.073 |
| Proteinuria (g/g creatinine) | 2.46 ± 0.73 | 1.83 ± 0.92 | 0.005 |
Data are presented as number (% of total) or means ± SD
BMI Body mass index, CKD Chronic kidney disease, eGFR estimated glomerular filtration rate, estimated with Modification of Diet in Renal Disease, NS nephrotic syndrome
aGroup of ‘No progression’ include patients that had spontaneous remission or remission through immunosuppressant or stable status of disease